Depression
From the Journals
Effective alternatives to psychotherapy for borderline personality disorder
At 12 months, there was a mean 28.91-point (23.8%) drop in interpersonal problems, reported lead author Dr. Andrew Chanen.
From the Journals
Novel antidepressant shows promise
as add-on therapy
Adjunctive treatment with the novel oral medication REL-1017 (esmethadone) is effective in adults with major depressive disorder (MDD) who have...
Mental Health Consult
Psychiatry and semantics
I am a psychiatrist, which means I am a mental health professional, which means I work with people with mental illness....
From the Journals
New data support a causal role for depression in Alzheimer’s
“If we can treat the depression early on, we may help reduce risk for dementia for our patients later in life,” said coinvestigator Dr. Aliza P....
From the Journals
Opioid agonist therapy guards against self-harm, suicide
These results highlight the importance of a ‘transition’ period when stopping OAT, said study investigator Dr. Prianka Padmanathan.
Commentary
Confusing messages on COVID taking a psychological toll
“I am worried about the impact of these confusing messages on the psyche of our patients.
From the Journals
New understanding of suicide attempts emerges
The genetic underpinnings of suicide attempts are partially shared and partially distinct from those of related psychiatric disorders.
Commentary
Treating homeless patients: Book offers key insights
The book serves as a reminder for clinicians treating this population about why they continue to do this work, said Dr. Aislinn Bird.
From the Journals
Fish oil: ‘No net benefit’ for depression prevention?
The VITAL-DEP study included more than 18,000 adult partipants who were free of clinically relevant depressive symptoms at baseline.
Commentary
COVID-19 and coping with superimposed traumas
Empathy burnout is also a real and important facet in the equation, said Dr. Cassondra Feldman.
News
FDA grants new indication to lumateperone (Caplyta) for bipolar depression
This makes lumateperone the only FDA-approved drug for adults with depressive episodes associated with bipolar I and II disorder.